We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT... Personalis Inc is a provider of advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions. Show more
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal®...
Blood-based assay uses personalized tumor-informed approach designed to detect cancer recurrence early with an ultra-sensitive approach Personalis, Inc. (Nasdaq: PSNL), a leader in advanced...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on November 15, 2023 and...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided...
0001527753false00015277532024-02-282024-02-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, February 28...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor conferences: BTIG MedTech, Digital...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.671140939597 | 1.49 | 1.55 | 1.39 | 199820 | 1.43977254 | CS |
4 | 0.16 | 12.1212121212 | 1.32 | 1.8 | 1.31 | 403086 | 1.61823567 | CS |
12 | -0.48 | -24.4897959184 | 1.96 | 2.31 | 1.12 | 411048 | 1.5590977 | CS |
26 | 0.27 | 22.3140495868 | 1.21 | 2.38 | 0.8906 | 502960 | 1.45849096 | CS |
52 | -1.1 | -42.6356589147 | 2.58 | 3.27 | 0.8906 | 371113 | 1.66610322 | CS |
156 | -20.11 | -93.1449745252 | 21.59 | 28.47 | 0.8906 | 457175 | 8.42444143 | CS |
260 | -22.22 | -93.7552742616 | 23.7 | 53.46 | 0.8906 | 495766 | 14.77273045 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions